Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Alterity Therapeutics ( (AU:ATH) ) has issued an announcement.
Alterity Therapeutics has issued 27,000,000 unlisted options with an exercise price of $0.009, expiring on 15 April 2031, as part of its employee incentive arrangements. The move underscores the company’s reliance on equity-based compensation to attract and retain talent while potentially diluting existing shareholders if the options are exercised, a common practice among growth-focused biotech firms.
The most recent analyst rating on (AU:ATH) stock is a Buy with a A$0.01 price target. To see the full list of analyst forecasts on Alterity Therapeutics stock, see the AU:ATH Stock Forecast page.
More about Alterity Therapeutics
Alterity Therapeutics Limited, listed on the ASX under the code ATH, operates in the biotechnology and pharmaceutical sector, focusing on therapeutics development. The company utilises employee incentive schemes that involve the issuance of unquoted equity securities such as options to align staff interests with long-term shareholder value.
Average Trading Volume: 5,614,265
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$97.88M
For an in-depth examination of ATH stock, go to TipRanks’ Overview page.